SIA
TEVA icon

Stancorp Investment Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Stancorp Investment Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$60K Buy
963
+558
+138% +$32.4K 0.03% 269
2014
Q4 		$23K Buy
+405
New +$22.6K 0.01% 335

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Stancorp Investment Advisers's TEVA Position: Q1 2015 in Review

Stancorp Investment Advisers increased its Teva Pharmaceuticals (TEVA) stake by 138% in Q1 2015, buying an estimated $32.4K and bringing the position to 963 shares worth $60K. The position accounts for 0.03% of the portfolio, ranked #269.

Stancorp Investment Advisers first reported a position in TEVA in Q4 2014 and has held it in 2 quarters since. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

  • Stancorp Investment Advisers held 963 shares of Teva Pharmaceuticals worth $60K as of Q1 2015.
  • Stancorp Investment Advisers bought 558 Teva Pharmaceuticals shares in Q1 2015, an estimated $32.4K.
  • Teva Pharmaceuticals made up 0.03% of Stancorp Investment Advisers's portfolio in Q1 2015, its #269 holding.
  • Stancorp Investment Advisers first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 2 quarters since.
  • 821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.